Navigation Links
Drug Combo Tied to Kidney Risk With Some Cardiac Surgeries
Date:2/7/2008

Aprotinin plus ACE inhibitor associated with renal woes during off-pump surgery, U.K. study finds

THURSDAY, Feb. 7 (HealthDay News) -- While use of the clotting drug aprotinin (Trasylol) appears safe during on-pump cardiac surgeries, combining it with angiotensin-converting enzyme (ACE) inhibitors during off-pump cardiac surgery shows a significant risk of postoperative kidney dysfunction, British researchers say.

The study was prompted by previous research that noted an association between use of aprotinin -- which reduces the risk of bleeding during complicated surgeries -- and renal failure. Drug maker Bayer voluntarily suspended worldwide marketing of aprotinin after preliminary findings from a Canadian study (BART) suggested the drug increased the risk of death. That trial was halted in October 2007. Shortly after that, the U.S. Food and Drug Administration pulled the drug from the American market.

For this study, researchers analyzed the cases of 9,875 cardiac surgery patients. Most of the patients (5,434) had on-pump cardiac surgery, which means their hearts were stopped and they were hooked up to a heart-bypass machine during surgery. The other patients had off-pump cardiac surgery -- doctors operated on their beating hearts.

Among patients who had on-pump surgery, there was no significant association between aprotinin and postoperative renal dysfunction, irrespective of ACE inhibitor use. However, aprotinin was associated with a more than twofold increased risk of renal dysfunction among the 848 patients who had off-pump cardiac surgery and received both aprotinin and ACE inhibitors.

"We recommend that it might be beneficial for patients to discontinue any use of an ACE inhibitor before elective off-pump surgery, particularly patients with a history of renal impairment," wrote Dr. Ronelle Moulton and Kai Zacharowski, from the department of anesthesia, Bristol Royal Infirmary, United Bristol Healthcare Trust.

Their study was published in this week's issue of The Lancet.

A complete analysis of the BART findings will not be known for some time, Dr. Derek Hausenloy, of The Hatter Cardiovascular Institute, University College London Hospital and Medical School, and colleagues wrote in an accompanying comment.

"While waiting for that analysis, the use of aprotinin in the U.S. and in some European countries has been necessarily restricted, with the consequence that some high-risk patients having cardiac surgery might not receive optimum therapy," Hausenloy and colleagues noted.

More information

The U.S. National Heart, Lung, and Blood Institute has more about heart surgery.



-- Robert Preidt



SOURCE: The Lancet, news release, Feb. 7, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Combo Therapy Shows Promise in Treating Brain Tumors
2. Combo Treatment Best for Elderly Lymphoma Patients
3. Combo Therapy Cuts Prostate Cancer Death Rates
4. Drug Combo Halves Death Risk for Severe COPD Patients
5. Aspirin, Hormone Therapy Combo Can Shorten Lives of Prostate Cancer Patients
6. New Combo Treatment Extends Kidney Cancer Survival
7. Drug Combo With Antibiotic May Slow MS Progression
8. Combo PET/CT Scan Helps Spot Breast Cancers Spread
9. Drug Combos Effective Against Rheumatoid Arthritis
10. Drug Combo Boosts Multiple Myeloma Survival
11. CPR, Defibrillator Combo Boosts Cardiac Incident Survival
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug Combo Tied to Kidney Risk With Some Cardiac Surgeries
(Date:1/19/2017)... ... January 19, 2017 , ... Bio-Optronics Inc. ... a modern CTMS workflow designed to seamlessly integrate and streamline the way researchers ... a single page, maximizing usability and improving efficiency significantly for users – a ...
(Date:1/19/2017)... ... January 19, 2017 , ... Students interested in video ... Awareness Scholarship competition., The winner will earn a $1,000 scholarship and have his or ... Feb. 1, and the deadline is May 31, with the winner announced on June ...
(Date:1/19/2017)... ... 2017 , ... Workrite Ergonomics announced this week the launch ... panel system was designed to deliver the ideal blend of acoustic and visual ... the visual privacy required to maintain concentration levels and increase productivity. The tranquility ...
(Date:1/19/2017)... ... January 19, 2017 , ... Allegheny Health Network (AHN) officials today ... access to the Network’s programs and services in the greater Pittsburgh region. Starting January ... will be offered one for that same afternoon. , AHN is ...
(Date:1/19/2017)... ... January 19, 2017 , ... Rountree Brady ... services to communities throughout eastern Georgia, is embarking on a charity effort to ... disease kills more Americans every year than anything else, yet risk factors associated ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... Conference Call and Webcast to Follow Vanda Pharmaceuticals Inc. ... results for the fourth quarter of 2016 on Wednesday, February 15, ... ... PM ET on Wednesday, February 15, 2017, during which management will ... other corporate activities. To participate in the conference call, please dial ...
(Date:1/19/2017)... , Jan. 19, 2017 This report on ... and future scenario of the global market. Large number ... consumption. Severe chronic constipation is a major side effect ... laxatives. Hence, novel targeted therapy has been prescribed to ... launch of targeted medicines, and growing awareness about the ...
(Date:1/19/2017)... , Jan. 19, 2017  Stealth BioTherapeutics Inc. ... to treat mitochondrial dysfunction, today announced new additions to ... M.D., as Chief Medical Officer, and Daniel Geffken ... announced that Jim Carr , Pharm.D. has been ... "We are pleased to welcome Doug and Daniel to ...
Breaking Medicine Technology: